Bifidobacterium Catenulatum

Many case-control studies find lower bifidobacteria in people with gut or systemic disease than in controls. This species, or the B. catenulatum/pseudocatenulatum group when an assay cannot separate the two, appears in studies of irritable bowel syndrome, celiac disease, colorectal cancer, chronic liver disease, and peritoneal dialysis.

This is a research marker, not a diagnosis. There is no cutoff that separates normal from abnormal, and a single low reading does not mean you have any of those conditions. The useful question is narrower: how this fiber-fermenting species fits with your symptoms, antibiotic history, lab method, and the rest of your stool panel.

What This Test Actually Measures

This is a stool DNA measurement. The lab extracts microbial DNA from a stool sample. PCR copies target DNA so it can be counted. The result is a count or relative abundance of bacterial DNA, not a chemical made by your own body.

One practical wrinkle matters. B. catenulatum and B. pseudocatenulatum share so much genetic sequence that many common DNA-based methods cannot cleanly separate them and report the two together as the B. catenulatum group. The distinction matters because B. pseudocatenulatum has its own associations in the allergy literature.

Extraction method matters more here than for many stool markers. Bifidobacteria have thick cell walls, and DNA extraction without mechanical bead-beating can miss them. A zero from a lab that does not use bead-beating may be a lab artifact, not biology.

What It Does in Your Gut

This species ferments complex sugars and fibers your own enzymes cannot break down. Its main products are acetate and lactate. Both are small acids made during fiber fermentation.

Acetate and lactate can feed other colon bacteria that make butyrate. Butyrate is the main fuel for colon lining cells and helps tighten the seals between those cells. So this species is better understood as a feeder of the gut-barrier system than as a direct barrier marker.

After weaning, the B. catenulatum group becomes one of the adult-type bifidobacteria. Total bifidobacteria are usually lower in adults than in breast-fed infants and often decline further in old age.

Irritable Bowel Syndrome

The largest species-level gap comes from IBS. In one study, B. catenulatum made up about 6% of the bifidobacterial share in people with IBS versus about 19% in healthy controls. The same pattern appeared in stool and in samples brushed directly from the upper small intestine.

That study was a snapshot. It cannot tell you whether lower B. catenulatum helps drive IBS symptoms or whether an inflamed, fast-moving gut is simply a hard place for it to live. A low reading next to long-standing bloating, pain, or irregular stools is a clue to interpret beside other tests, not an IBS test.

Celiac Disease and Inflammatory Bowel Conditions

In children with celiac disease, biopsy samples from the upper small intestine were less likely to contain the B. catenulatum group than control biopsies, including in children whose disease was not active. The stronger quantitative signal in that study was lower total Bifidobacterium and B. longum, not this species alone.

Mucosal studies in colorectal cancer, diverticulitis, and inflammatory bowel disease also find bifidobacterial abnormalities, but most of the differences are at the genus level or involve other species. In treatment-naive Crohn's disease, low baseline Bifidobacterium at the genus level predicted non-response to infliximab, and modeling linked B. catenulatum to bile acid metabolism. Bile acids help digest fat and also signal to immune cells. This remains an experimental treatment-stratification signal.

Systemic Disease and Organ Failure

Depletion is not confined to gut diagnoses. Adults on peritoneal dialysis were less likely to have B. catenulatum detected in stool than age-matched controls. People with hepatitis B-related cirrhosis also carried the B. catenulatum/pseudocatenulatum group less often than healthy controls.

The pattern has the same shape across these conditions: chronic illness, thinner bifidobacterial populations. What is missing is proof that the bacterial loss came first or that restoring it changes the disease.

Colorectal Cancer and Immunotherapy

A 2024 colorectal cancer study that counted bacterial DNA in stool found lower Bifidobacterium overall in cancer cases than controls, but it did not measure B. catenulatum specifically. A 2026 Gut study was more specific: B. catenulatum was depleted in human colorectal cancer stool cohorts, then oral B. catenulatum slowed tumor growth and improved how well an anti-PD-1 immunotherapy drug worked in mouse colorectal cancer models. The proposed mediator was acetate acting on cancer-killing immune cells.

That is mostly mechanistic evidence, and the treatment part of it comes from mice. It does not mean a low stool reading raises your cancer risk or that a high one protects you. Nobody has shown that changing this number changes cancer outcomes in people.

Why Low Is Not Always Bad, and High Is Not Always Good

Most adult disease studies point one way: less of this species, more disease. Two findings run the other direction.

In infants at high risk of allergy because of family history, carrying B. catenulatum at 3 months was associated with about four and a half times the odds of eczema. In adolescents under high chronic stress, B. catenulatum was more abundant than in low-stress peers and was linked with altered sugar metabolism and cholesterol-related signals.

This is not a good-number, bad-number marker. It is a context marker. The same organism can mean something different in a three-month-old immune system, a stressed adolescent, and an adult colon trying to feed butyrate producers.

Why a Single Reading Can Fool You

Antibiotics are the biggest confounder. A five-day course of amoxicillin-clavulanic acid reduced total fecal bifidobacteria and lowered detection of the B. catenulatum/pseudocatenulatum group. The community fingerprint was still different from baseline two months later.

A few other things can distort the picture:

• Lab method: without mechanical bead-beating during DNA extraction, bifidobacteria may go undetected. Comparing labs with different extraction protocols is weak evidence.
• The group problem: if your assay reports the B. catenulatum group, your number includes B. pseudocatenulatum too.
• Your own genetics: people with non-functional FUT2 variants, often called non-secretors, carry this species less often. About one in five people of European ancestry are non-secretors, so a low or near-zero result can partly reflect inherited biology.
• Stool versus mucosa: stool captures what is passing through. It may not match what is attached to the gut lining.

Tracking Your Trend

With no validated reference range, your previous result is the best benchmark. That makes repeat testing useful only if you use the same lab and collect under comparable conditions.

The gut community varies within the same person. A one-year study of healthy adults found meaningful within-person variation even though each person kept a recognizable microbial fingerprint. One number tells you little; a pattern over time says more.

A low value after antibiotics should be labeled as post-antibiotic until a later sample proves recovery. Switching labs mid-series can create a fake change because extraction methods and DNA targets differ.

How to Read It Beside Other Markers

This number carries more meaning when paired with markers that measure the gut itself: fecal calprotectin, pancreatic elastase, celiac antibodies, total Bifidobacterium, butyrate producers, and stool short-chain fatty acids.

A single depleted species with normal inflammation markers says something different from broad bifidobacterial depletion with raised calprotectin. The pattern matters more than the species alone.